In the IR-D group, the expression of IL-6 was decreased and the Bcl-2 was increased when compared with the IR group.

Dexmedetomidine suppresses hepatic IR injury and the protective mechanism appears to involve the decrease of IL-6 and upregulation of Bcl-2 expression, which result in the attenuation of inflammatory response and the…[Read more]